Patents by Inventor Christopher R. Conlee

Christopher R. Conlee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190292224
    Abstract: Provided herein are peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disease.
    Type: Application
    Filed: January 30, 2019
    Publication date: September 26, 2019
    Inventors: Vincent Guerlavais, Christopher R. Conlee, Scott Paul Lentini
  • Patent number: 10286086
    Abstract: The present disclosure provides alternative nucleosides, nucleotides, and nucleic acids, and methods of using them.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: May 14, 2019
    Assignee: ModernaTX, Inc.
    Inventors: Atanu Roy, Christopher R. Conlee, Antonin De Fougerolles, Andrew W. Fraley, Gabor Butora, Matthew Stanton
  • Patent number: 10227380
    Abstract: Provided herein are peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disease.
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: March 12, 2019
    Assignee: AILERON THERAPEUTICS, INC.
    Inventors: Vincent Guerlavais, Christopher R. Conlee, Scott Paul Lentini
  • Patent number: 8987414
    Abstract: Provided herein are peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disease.
    Type: Grant
    Filed: February 14, 2013
    Date of Patent: March 24, 2015
    Assignee: Aileron Therapeutics, Inc.
    Inventors: Vincent Guerlavais, Christopher R. Conlee, Scott Paul Lentini
  • Patent number: 8222261
    Abstract: The present invention relates to novel compounds that are useful in the treatment of metabolic disorders, particularly Type II diabetes mellitus and related disorders, and also to the methods for the making and use of such compounds.
    Type: Grant
    Filed: January 13, 2009
    Date of Patent: July 17, 2012
    Assignee: GlaxoSmithKline, LLC
    Inventors: Subba R Katamreddy, Richard Dama Caldwell, Dennis Heyer, Vincente Samano, James Benjamin Thompson, Andrew J Carpenter, Christopher R Conlee, Eric Eugene Boros, Brian D Thompson
  • Publication number: 20120077812
    Abstract: The present invention relates to novel compounds that are useful in the treatment of metabolic disorders, particularly type II diabetes mellitus and related disorders, and also to the methods for the making and use of such compounds.
    Type: Application
    Filed: November 30, 2011
    Publication date: March 29, 2012
    Inventors: JING FANG, Jun Tang, Andrew J. Carpenter, Gregory Peckham, Christopher R. Conlee, Kien S. Du, Subba Reddy Katamreddy
  • Patent number: 8101634
    Abstract: The present invention relates to novel compounds that are useful in the treatment of metabolic disorders, particularly type II diabetes mellitus and related disorders, and also to the methods for the making and use of such compounds.
    Type: Grant
    Filed: December 5, 2007
    Date of Patent: January 24, 2012
    Assignee: GlaxoSmithKline LLC
    Inventors: Jing Fang, Jun Tang, Andrew J Carpenter, Gregory Peckham, Christopher R Conlee, Kien S Du, Subba Reddy Katamreddy
  • Publication number: 20100105654
    Abstract: A variety of small molecule, guanidine-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases when administered to subjects. The compounds have the structures VA, VB, VIIA and VIIB where the values of the variables are defined herein.
    Type: Application
    Filed: October 23, 2009
    Publication date: April 29, 2010
    Inventors: Rustum S. BOYCE, Natalia Aurrecoechea, Daniel Chu, Aaron Smith, Christopher R. Conlee, Brian D. Thompson, Judith de Armas Kuntz, David L. Musso, Kevin K. Barvian, Stephen A. Thomson, William R. Swain, Kien S. Du, Brian A. Chauder, Jason D. Speake, Michael J. Bishop
  • Publication number: 20100029650
    Abstract: The present invention relates to novel compounds that are useful in the treatment of metabolic disorders, particularly type II diabetes mellitus and related disorders, and also to the methods for the making and use of such compounds.
    Type: Application
    Filed: December 5, 2007
    Publication date: February 4, 2010
    Inventors: Jing Fang, Jun Tang, Andrew J. Carpenter, Gregory Peckham, Christopher R. Conlee, Kien S. Du, Subba Reddy Katamreddy
  • Patent number: 7625909
    Abstract: A variety of small molecule, guanidine-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases when administered to subjects. The compounds have the structure IA, IB, and IC where the values of the variables are defined herein.
    Type: Grant
    Filed: May 21, 2004
    Date of Patent: December 1, 2009
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Rustum S. Boyce, Natalia Aurrecoechea, Daniel Chu, Aaron Smith, Christopher R. Conlee, Brian D. Thompson, Judith de Armas Kuntz, David L. Musso, Kevin K. Barvian, Stephen A. Thomson, William R. Swain, Kien S. Du, Brian A. Chauder, Jason D. Speake, Michael J. Bishop